ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Houston, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Non-Small-Cell Lung Carcinoma

Adenocarcinoma trials near Houston, TX, USA:

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION)

to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Drug: NG350A (Cohort C)
Drug: Nab-paclitaxel (nP) (Cohort A, B and C)

Phase 1

Cancer Insight

Houston, Texas, United States and 5 other locations

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (DECIST)

of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after s...

Enrolling
Pancreatic Adenocarcinoma
Pancreatic Adenosquamous Carcinoma
Biological: Autologous DC Therapy

Phase 1

Diakonos Oncology Corporation

Houston, Texas, United States and 2 other locations

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA)

metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEA).ABBV-400 and Budigalimab are investigational drugs being...

Enrolling
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Esophageal Adenocarcinoma
Drug: Budigalimab
Drug: ABBV-400

Phase 2

AbbVie
AbbVie

Houston, Texas, United States and 11 other locations

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

Houston, Texas, United States and 103 other locations

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line ne...

Enrolling
Pancreatic Ductal Adenocarcinoma
Drug: Pembrolizumab
Drug: Folfirinox

Phase 2

Baylor College of Medicine
Baylor College of Medicine

Houston, Texas, United States and 2 other locations

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Enrolling
PDAC - Pancreatic Ductal Adenocarcinoma
PDAC
Drug: 5-fluorouracil
Drug: leucovorin

Phase 3

Revolution Medicines
Revolution Medicines

Houston, Texas, United States and 46 other locations

Locations recently updated

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

esophageal adenocarcinoma.This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will b...

Enrolling
Gastroesophageal Adenocarcinoma
Esophageal Cancer
Drug: Levoleucovorin
Drug: Capecitabine

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Houston, Texas, United States and 39 other locations

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination wi...

Enrolling
Locally Advanced Pancreatic Adenocarcinoma
Drug: SD-101
Biological: anti-PD-1

Phase 1

TriSalus Life Sciences

Houston, Texas, United States

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish)

as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma...

Active, not recruiting
Gastric Adenocarcinoma
Gastric Cancer
Drug: Tislelizumab 200mg
Drug: DKN-01 400mg

Phase 2

Leap Therapeutics

Houston, Texas, United States and 47 other locations

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropy...

Enrolling
Metastatic Pancreatic Adenocarcinoma
Drug: Capecitabine
Drug: Ivaltinostat

Phase 1, Phase 2

CG Pharmaceuticals

Houston, Texas, United States and 15 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems